Departing from industry norms, Curie.Bio intentionally allocates a large equity stake to founders. They see this not just as fair but as a utilitarian strategy to gain a competitive advantage in sourcing the rarest and most valuable scientific ideas, which ultimately drives fund returns.

When you find a special founder, all other rules (ownership targets, valuation) can be broken. Andreessen echoes VC pioneer Arthur Rock's conclusion: he would have been a better investor by focusing 100% on the founder's resume and ignoring the business plan entirely. Great people trump everything else.

Top-performing, founder-led businesses often don't want to sell control. A non-control investment strategy allows access to this exclusive deal flow, tapping into the "founder alpha" from high skin-in-the-game leaders who consistently outperform hired CEOs.

Many VCs fixate on hitting a specific ownership percentage, which can be a misleading heuristic. The ultimate goal is maximizing returns for LPs. It's better to own a smaller piece of a generationally massive company than a larger piece of a modest one if the exit potential is large enough.

A universal ownership target is flawed. The strategy should adapt to a company's traction. For rare, breakout companies with undeniable product-market fit ('absolutely working'), a VC should take any stake they can get. For promising but unproven ideas ('could work'), they must secure high ownership to compensate for the greater risk.

A truly exceptional founder is a talent magnet who will relentlessly iterate until they find a winning model. Rejecting a partnership based on a weak initial idea is a mistake; the founder's talent is the real asset. They will likely pivot to a much bigger opportunity.

In early-stage investing, the quality of the founder can be more important than the initial business concept. A strong founder is seen as someone who will eventually find success, even if the first idea requires a pivot.

For promising venture-stage companies, price sensitivity is a losing strategy. The truly exceptional opportunities attract significant interest, driving up valuations. According to Andreessen, the mistake of omission (passing on a future giant) far outweighs the mistake of overpaying slightly for a winner.

The quality of the founder is the single most important variable. A great founder with a mediocre plan will outperform a mediocre founder with a great plan. The best investment strategy is to back exceptional people and give them leeway, as they will create upside that breaks all precedents.